Stock DARE DARÉ BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
0.3059 USD +5.77% Intraday chart for Daré Bioscience, Inc. +9.25% -1.00%
04-23 Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 CI
03-28 Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024

Business Summary

Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Number of employees: 25

Sales per Business

USD in Million2022Weight2023Weight Delta
Women's Health
100.0 %
10 100.0 % 3 100.0 % -71.92%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
10 100.0 % 3 100.0 % -71.92%

Managers

Managers TitleAgeSince
Sabrina Johnson FOU
 Founder 57 31/12/14
Annie Thurman CTO
 Chief Tech/Sci/R&D Officer - 31/12/21
Jessica Hatheway CTO
 Chief Tech/Sci/R&D Officer - 31/12/21
Christine Mauck CTO
 Chief Tech/Sci/R&D Officer - 31/12/15
David Friend CTO
 Chief Tech/Sci/R&D Officer - 05/06/18
Mark Walters COO
 Chief Operating Officer 69 31/12/14
MarDee Haring-Layton AUD
 Comptroller/Controller/Auditor 47 30/09/18

Members of the board

Members of the board TitleAgeSince
Robin Steele BRD
 Director/Board Member 68 31/12/14
Cheryl Blanchard BRD
 Director/Board Member 59 19/11/19
William Rastetter CHM
 Chairman 75 31/12/13
Sabrina Johnson FOU
 Founder 57 31/12/14
Jessica Grossman BRD
 Director/Board Member 52 08/04/18
Susan Kelley BRD
 Director/Board Member 69 30/09/14
Gregory Matz BRD
 Director/Board Member 64 12/09/18
Sophia Ononye-Onyia BRD
 Director/Board Member 40 15/04/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 100,581,900 98,919,352 ( 98.35 %) 0 98.35 %

Shareholders

NameEquities%Valuation
Vanguard Global Advisers LLC
3.499 %
3,448,612 3.499 % 2 M $
Geode Capital Management LLC
0.9853 %
971,119 0.9853 % 475 848 $
Sabrina Johnson
0.9761 %
962,062 0.9761 % 471 410 $
Renaissance Technologies LLC
0.7299 %
719,400 0.7299 % 352 506 $
Lisa Walters-Hoffert
0.4500 %
443,512 0.4500 % 217 321 $
BlackRock Institutional Trust Co. NA
0.3935 %
387,837 0.3935 % 190 040 $
STATE STREET CORPORATION
0.2513 %
247,710 0.2513 % 121 378 $
Robin Steele
0.2498 %
246,171 0.2498 % 120 624 $
Northern Trust Investments, Inc.(Investment Management)
0.1860 %
183,302 0.1860 % 89 818 $
T. Rowe Price International Ltd.
0.1277 %
125,900 0.1277 % 61 691 $

Company contact information

Daré Bioscience, Inc.

3655 Nobel Drive Suite 260

92122, San Diego

+

http://www.darebioscience.com
address Daré Bioscience, Inc.(DARE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Daré Bioscience, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.3059 USD
Average target price
4 USD
Spread / Average Target
+1,207.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DARÉ BIOSCIENCE, INC. Stock Daré Bioscience, Inc.
-1.00% 30.77M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DARE Stock
  4. Company Daré Bioscience, Inc.